If you live in Florida and you have spent any time online in the last year, you have seen the ads. Compounded semaglutide for $199 a month. Tirzepatide injections shipped to your door, no insurance required. "Lose 30 pounds in 90 days."

The marketing is everywhere — on Spanish-language radio in Miami, on billboards along I-95, in your Instagram feed, in pop-ups while you are reading the news.

Some of these services are run by actual physicians providing legitimate care. Some are run by companies that found a regulatory loophole and exploited it as fast as they could. The framework below is meant to help readers tell the difference, with a focus on Florida, where the market is more saturated and the risks are slightly higher than the national average.

What is actually being prescribed

The GLP-1 class, briefly

The class of medications people commonly call "GLP-1s" includes:

Semaglutide — sold as Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for chronic weight management).
Tirzepatide — sold as Mounjaro (type 2 diabetes) and Zepbound (weight management). Tirzepatide is technically a GLP-1/GIP dual agonist and is, on average, more effective for weight loss than semaglutide.
Liraglutide — older daily injection, sold as Saxenda for weight loss.

Branded vs compounded — and why the price gap matters

The branded versions (Wegovy, Zepbound, Ozempic, Mounjaro) are manufactured by Novo Nordisk and Eli Lilly. They run $1,000–$1,400 per month at retail.

Coverage is uneven. Florida Blue, Aetna, Cigna, and UnitedHealthcare all cover them under specific plans, usually with prior authorization, and almost always require a documented BMI of 30 or higher (or 27+ with a comorbidity) for the weight-loss versions.

What you will see advertised at $199–$400 a month is almost always compounded semaglutide or compounded tirzepatide — versions made by compounding pharmacies, not the manufacturers.

Compounded GLP-1s: legal status as of 2026

The shortage rule, in plain English

This is the part most ads do not explain clearly. Compounded medications are legal under FDA regulations, but only under specific conditions — most importantly, they are typically allowed when the brand-name drug is on the FDA's official shortage list. Both semaglutide and tirzepatide were on that list for most of 2023–2024.

The shortage is over — and the rules tightened

The FDA officially declared the tirzepatide shortage resolved in late 2024, and the semaglutide shortage resolved in February 2025.

A series of court rulings and FDA guidance documents through 2025 have significantly tightened what compounding pharmacies can produce. As of 2026, the legitimate use cases for compounded GLP-1s are much narrower than they were two years ago.

Any clinic still selling them at scale needs a defensible medical justification — like a documented adverse reaction to the brand version, or a specific dosing need the brand cannot meet.

What this means for the patient

This matters because if you are paying $250 a month for compounded semaglutide from a Florida telehealth platform that does not ask many questions, the regulatory ground under that arrangement has shifted, and not in your favor.

What a legitimate telehealth weight-loss program looks like

Five features of a well-run program

Florida has plenty of these. The features that distinguish them from the questionable ones are pretty consistent:

Real labs before prescribing. A reasonable program will require recent bloodwork — A1c, fasting glucose, lipid panel, thyroid function, kidney function, sometimes liver enzymes. If a clinic prescribes a GLP-1 based only on a five-question intake form, that is a red flag.
BMI and medical history actually matter. A legitimate prescriber will ask about your weight, height, family history of medullary thyroid cancer or MEN2, history of pancreatitis, and whether you have had bariatric surgery. These are not bureaucratic — they are the actual contraindications.
The prescriber is a real, licensed Florida physician, PA, or NP. Verify the NPI. The Florida Department of Health license lookup tells you if the clinician is in good standing.
You are seen for follow-ups. GLP-1 dosing is gradual — you start low and titrate up over months. You should be checking in with a clinician at regular intervals, not just receiving auto-shipped vials.
The pharmacy is identifiable and licensed. Florida-licensed pharmacies (and FDA-registered out-of-state pharmacies shipping into Florida) are searchable. If the platform will not tell you which pharmacy is dispensing your medication, that is a problem.

Common red flags

What to walk away from

"No labs required" — labs are required for safe prescribing of these medications. Period.
"Prescribed within minutes" — this almost always means an asynchronous form review with no real clinical evaluation.
Dosing higher than the FDA-approved schedule — some compounding clinics jump dosing aggressively to maximize early weight loss. This drives nausea, vomiting, and dehydration, especially in older Floridians.
Subscription auto-renewal that is hard to cancel — this is regulated under Florida's auto-renewal disclosure law, but enforcement is uneven.
Marketing in clinical settings (gyms, med spas) where the prescribing clinician is not physically present or available.

If you have insurance, start there

Try the brand-name PA before going direct-pay

Before signing up for a $300-a-month direct-pay program, it is worth running a prior authorization through your insurance for the brand-name version first.

Florida Blue, in particular, covers Wegovy and Zepbound under specific plans for patients who meet the criteria. Even when an initial PA is denied, the appeal process is worth pursuing, especially with documented prior weight loss attempts and a letter of medical necessity from the prescribing clinician.

If insurance won't cover it

If insurance will not cover it, then yes, a direct-pay telehealth program may be the right path. Just choose one with a real prescribing relationship, real labs, and a real Florida-licensed clinician you can identify by name and NPI.

The bottom line

The drugs are not the problem — the prescribing model often is

GLP-1 medications, used appropriately, are among the most effective tools we have for managing obesity and type 2 diabetes. The problem is not the drugs — it is the prescribing model some companies have built around them.

In Florida especially, the gap between a careful telehealth weight-loss practice and a high-volume injection-by-mail operation has gotten wider, not narrower, in 2026.

Three things to verify, every time

Verify the prescriber. Verify the pharmacy. Verify that someone with a medical license will see you again in three months. If any of those is missing, it is not actually healthcare — it is a subscription.

Disclaimer: This article provides general medical information and is not personalized medical advice. GLP-1 medications have specific contraindications and side effects that must be evaluated by a licensed clinician familiar with your medical history.

Online Weight Loss Doctors and GLP-1 Prescribers in Florida: What Is Legitimate, What Is Risky